We are excited to end 2016 with a strong scientific communications presence at three major congresses. A total of 48 abstracts, including 16 oral presentations, have been accepted across:
ASH: the 58th American Society of Hematology Annual Meeting
3-6 December 2016, San Diego, USA
WCLC: the 17th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer
4-7 December 2016, Vienna, Austria
SABCS: the San Antonio Breast Cancer Symposium
4-7 December 2016, Vienna, Austria
3-6 December 2016, San Diego, USA
4-7 December 2016, Vienna, Austria
5-10 December 2016, San Antonio, USA.
American Society of Hematology Annual Meeting (ASH)
Our presence at ASH 2016 will focus on new data in patients with difficult-to-treat chronic lymphocytic leukaemia. This comes less than a year after we announced a majority investment in Acerta Pharma, which is becoming our haematology Centre of Excellence.
World Conference on Lung Cancer (WCLC)
At WCLC 2016, we will shine the spotlight on our lung portfolio, with confirmatory results in patients with advanced non-small cell lung cancer (NSCLC), data on novel mutation testing methods for patients with NSCLC and latest research into patients with NSCLC and brain metastases.
LabTalk blog post by Dr Denny Clifford - “Early in my career as a practicing Pulmonary and Critical Care specialist I was fortunate to be a Principal Investigator on an AstraZeneca study, which led to a long relationship investigating new pharmaceuticals in the Respiratory field. In my 33 years as a practicing doctor I have diagnosed over 800 lung cancers, and dedicated my time to providing patients with the best possible care.”
.jpg/jcr:content/renditions/cq5dam.web.1200.AZ1582_Circulating_tumour_DNA (1).jpg)
November is Lung Cancer Awareness Month; an important occasion when we can pause to reflect on valuable diagnostic and treatment advances in our journey to improving cancer outcomes. These scientific discovery milestones continue to excite me, along with the wider scientific community, and provide hope to patients and their loved ones.
San Antonio Breast Cancer Symposium (SABCS)
At SABCS, our data presentation data will build on previous findings in women with advanced hormone-receptor positive breast cancer, including an analysis in women with and without metastases that have spread to the liver and/or lung, so-called visceral disease.
Page Atlas ID: 1024017.011
Date of next review: December 2017